01 June 2011

Calming inflation fears Slower growth in CY11.:Macquarie Research

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Calming inflation fears
Slower growth in CY11
This report contains detailed forecasts for the economies that we cover across
Asia, and the latter section sets out the prospects for individual economies. In
most cases, we think growth should slow significantly in CY11–12 after the postcrisis
rebound of 2009–10, but that it will need continued policy tightening to limit
inflation risks, with commodity prices adding to uncertainty.
So far this year, growth has generally been performing in line with our
expectations, with the obvious exception of Japan. However, our inflation
forecasts have risen, implicitly due to events outside of the region – mainly as a
result of commodity price movements.
Inflation is the focus
Our view that underlying inflation risks are not particularly severe – bearing in
mind this is the third year of recovery – has received support over the past
month, from both evidence of continued prudence from policy-makers and signs
that the recent burst of activity is beginning to slow.
Policy-makers showing reasonable prudence
Interest rate hikes have combined with exchange rate appreciation to lead to
tighter monetary conditions across most economies in the region. At the same
time, the pace of increase in foreign exchange reserves points to fundamental
upward pressure on exchange rates – coming from an undervalued position –
which, in turn, points to the potential for further currency appreciation, as
discussed a month ago.
China is an important part of the picture, and we are increasingly comfortable
with the idea that policy-makers are ahead of the curve. Credit tightening is
biting, which points to slower growth and a peak in inflation by the end of 2Q11.
And growth is starting to slow
There are also signs that the late CY10 rise in industrial production, driven by the
tech sector, is beginning to slow. This seemed to have been a short-term
reaction to a sluggish period in mid-CY10 rather than a reflection of a
fundamental acceleration in demand, so a slowdown is just growth reverting
towards trend.
The supply chain impact from the Tohoku earthquake seems likely to cause
short-term disruption in some areas, mostly in April and May. There is a risk that
slower underlying growth across the region is wrongly ascribed to the impact
from Japan, rather than being recognised as a more genuine shift.
Underlying inflation remains moderate
Moreover, core inflation remains the dog that is refusing to bark across the
region. This suggests a flaw in the basic idea that prices will rise because
capacity is tight and policy is loose. We have doubts about all three of the
components of the argument.

Larsen & Toubro Q4FY11 – Belying most concerns :: Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Larsen & Toubro
Q4FY11 – Belying most concerns
Event
 L&T declared its 4QFY11 results with strong operating results. Revenues
were below expectations but compensated by margins. Highlight of the
earnings was order inflows in 4QFY11 (up 27% YoY) and guidance which was
better than expected on every count.
 We believe there are clear signs of some pick-up in the investment activity.
L&T is the best way to play the turnaround, given its diversification. Reiterate
L&T as our top pick, with a revised target price of Rs2,093 (from Rs2,215) due
to slightly lower revenues. We remain 8% ahead of consensus in earnings.
Impact
 Order inflow surprised in FY11, fair bit of confidence on FY12 guidance:
L&T reported Rs300bn of order inflows in 4QFY11 as against expectations of
Rs150-200bn. The company did not announce most of the orders due to client
confidentiality reasons. Guidance of 15-20% order inflow growth in FY12 after
delivering 15% growth in FY11 is encouraging.  Order inflows in FY12 are
seen from gas-based power plants, road, oil and gas and fertilisers.
 Underlying margin performance robust, building lot of cushion for
margin pressure: L&T’s margin improved by 10bps to 15.2% in 4QFY11
despite non-cash charges like warranty provisioning for the  Delhi T3 terminal
project and forex loss, totalling to Rs2.5bn. Management’s guidance of flat
margins (witn max 50-75bps decline) is conservative, in our view, as the
company has 70bps cushion from the reversal of these non-cash charges. We
are building in 20bps decline in margins in FY12 to 12.6%.
 We remain bullish on revenues and ahead of guidance: We are
forecasting 28% revenue growth in FY12 (ahead of L&T’s guidance of 25%)
as we believe that 30% growth in the order book in FY12, coupled with strong
execution in domestic E&C (30% of the order book), will drive this growth.
Earnings and target price revision
 We revise our earnings and target price marginally by 4-5%. Our revised
target price is Rs2,093 (from Rs2,215 earlier).
Price catalyst
 12-month price target: Rs2,093.00 based on a Sum of Parts methodology.
 Catalyst: pick-up in order inflow and execution
Action and recommendation
 Consensus needs to upgrade its estimates: Consensus’ bearish call on
margins has been proven wrong in FY11. We believe that enough room exists
for consensus to upgrade its FY12 EPS estimate of Rs72 upwards.
 Worst is behind us on investment cycle: Strong revenue growth and order
inflow pickup  to us indicates that the worst of the investment cycle is over.
Strong activity in large scale orders is likely to pickup in 2HFY12.
 Stock trading at long term averages, maintain high conviction OP call:
L&T is available at a 30% discount to its long-term multiple of 21x. We retain it
as our top pick in the Indian large cap infrastructure space, as we remain
excited about its earnings growth.

Ashok Leyland : Q4 margins surprise, but not sustainable ::BofA Merrill Lynch

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Ashok Leyland
   
Q4 margins surprise, but not
sustainable
„Cut PO, Maintain Underperform
Q4 profit at Rs 3bn beat expectations, driven by 30% yoy sales growth at
Rs38.3bn, 6% ahead of estimates, resulting in stronger 35% EBITDA growth at
Rs 5.1bn. While we raise EPS forecasts by 8%-6% over FY12-13E to factor this
surprise, our PO is cut 6% to Rs 58 by imputing late cycle valuation multiple of
6.5x EV/EBITDA (earlier 7x), reflecting growth moderation.
Sales guidance unlikely to be met
Management guidance of 15% growth in FY12 seems aggressive, despite rising
contribution from exports. We expect domestic demand to lag peers, due to
(1) increased competition in trucks, (2) absence of JNNRUM orders, which
contributed to the 23% growth last year in buses (23% of sales), and (3) delayed
foray and weak franchise in light vehicles. We therefore retain sales growth
assumption of 11%/year at 104K units in FY12E and 116K units in FY13E.  
Margins an aberration
Q4 EBITDA margins increased 45bps yoy/470bps qoq to 13.3%, much sharper
than expected, despite one-time staff expenses (65bps), due to better sales mix
(defence supplies, spares, in-house engines) and higher production from
Uttarakhand (~24%). Despite continuing shift to tax-free unit, margins are likely to
be pulled down by increased sales of completely built U-trucks. Margin
assumptions are unchanged at 10.6%/10.4%, but EBITDA raised by 12%/10%.
Balance sheet issues
(1) Investments Rs 12bn (4x FY10), incl Rs 3bn conversion of advance to
associates to equity, (2) NWC 22 days’ sales (last yr 18 days’), to correct on
recovery of dated receivables, (3) Gearing higher at 90% (last year 71%), despite
favourable cycle, expected to remain similar on planned capex/investments.

Buy Sun Pharma: Can Money

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Fundamental Reasons:-
Sun Pharma is an India based global pharmaceutical major having its dominance in the field of high end specialty
arena such as psychiatry, neurology, cardiology etc. Company was incorporated in the year 1983 and since then,
company has penetrated deep into the various vital aspects of pharma industry . Growing in leaps & bounds, from
a very humble beginning, Sun Pharma becomes the largest pharma company in India by market valuation.
Company is having a very sounding presence in all aspects of drug manufacturing and a player to reckon with
specialized manufacturing capacities in the niche segments of API, formulation and R&D business. Company is
having its own brands in the 41 markets across the globe. In last decade, Sun Pharma has adopted a strategy of inorganic
expansion and gradually company has acquired US based Caraco Pharma Labs, Taro of Israel, Alkaloida
Chemical Company Exclusive Group Ltd, Chattem Chemicals etc to strengthen its presence in the operative verticals.
Beside having its special focus on the emerging market, Sun Pharma is having very deep penetration in the US, its
largest market. Company has built a strong pipeline of generics, directly and through our subsidiaries Caraco and
Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio.
Sun Pharma has reported its Q-3;2011 result, in line with market expectation. Mainly on account of the good
performance by its main vertical, Sun Pharma has reported an optimally good profit but adverse currency
movement, USFDA problem in CARACO case and higher inventory cost has eaten its profit. Though Company has
reported a surge in the topline and bottom-line, yet on OPM front it felt a punch. During the said Quarter, total
revenue of the company rose to Rs.760.57 Crore as compared to Rs.702.44 Crore in DEC’09, showing a YoY growth
of 8.28%, while total profit during the said period recorded at Rs 342.67 Crore against a figure of Rs 318.04 Crore on
Y/Y basis a rise of 7.74%. During the said period , Earning per share of the company also has improved
correspondingly and recorded to Rs 3.31 from a average value of Rs 3.07 as on 31st DEC; 2009. Despite a good
performance on financial front, OPM in the said quarters was reported at 42.54% against 45.32% on Y/Y basis.
Sun Pharma is expected to garner good revenue and profit in coming quarters because of following facts: - 1. Sun
Pharmaceutical Industries Ltd and MSD a unit of Merck Inc have entered into a partnership to market diabetes
drugs Sitagliptin and Sitaglipitin plus Metformin in the Indian market. 2. Successful revoking of the USFDA ban
from Caraco , will boost its generic business in US . 3. Acquisition of TARO will give access to Canadian & Israeli
markets in addition to a set base in US fro good growth .4. On account of new Healthcare policy, a large number of
people will be given medical benefits. Sun Pahrma is better placed among its Indian peers to tap this opportunity
mainly on account of its deep penetration and specialized products. 5. Deep international penetration, Company is
having own subsidiaries in African, European, Asian and American countries, which may provide business
opportunity for the company.6. Domestic pharma business in India may continue to grow in line with market.7. On
account of its subsidiaries “Chattem Chemicals” and ’ICN Hungary’, Sun pharma can formulate the drugs having
quantity of controlled substance like narcotics. This may help the company in exploiting a large sedative market
segment across the globe. All these indicate about the possible steps, instrumental to augment the value of
shareholders.
Healthcare sector is one of the vital sector for our economy. The healthcare sector is expected to reach US$ 280
billion by 2020. It is one of the fastest growing knowledge-based sectors in India and is expected to play a key role in
shaping India's rapidly developing economy. This growth may continue in near future and as a result of this, Indian
pharma industry may log in good numbers in coming quarters. Industry is growing at a compound annual growth
rate (CAGR) of 11.7 per cent during 2005–2015 and establish its presence among the world’s leading 10 markets.
However, owing to recovery issues in US and Euro Zone economies and in case of any abrupt withdrawal by FIIs, Sun
Parma may witness some temporary corrections before moving up.